IV Magnesium Therapy in Patients with Reduced Creatinine Clearance and Hypomagnesemia

1. Renal Function Thresholds for Magnesium Supplementation

Absolute contraindication: Creatinine clearance < 20 mL/min precludes any magnesium supplementation (oral or IV) because the kidneys cannot excrete excess magnesium, risking fatal hypermagnesemia. 1
CrCl 20–30 mL/min: Magnesium may be given only in life‑threatening emergencies (e.g., torsades de pointes, cardiac arrest) and requires extreme caution with continuous cardiac monitoring. 1
CrCl 30–60 mL/min: Use reduced magnesium doses and obtain serum magnesium concentrations every 24–48 h during the initial treatment period. 1
CrCl > 60 mL/min: Standard dosing is permissible with routine monitoring.

Do not administer IV magnesium to patients receiving continuous kidney replacement therapy (CKRT) or intermittent dialysis; the therapy itself removes magnesium. 1
Maintain serum magnesium by using dialysis solutions that contain magnesium ≥ 0.70 mmol/L; this is the safest method to achieve target levels. 1, 3
Avoid IV supplementation during CKRT because regional citrate anticoagulation markedly increases magnesium loss, leading to hypomagnesemia in 60–65 % of critically ill patients on CKRT; magnesium‑enriched dialysate is preferred. 1

Mild‑to‑moderate hypomagnesemia: 1 g magnesium sulfate (≈8 mEq) IV every 6 h for up to four doses (total ≤ 4 g).
Severe hypomagnesemia: 1–2 g IV over 15 min for rapid correction; alternatively, add 5 g (≈40 mEq) to 1 L of isotonic fluid and infuse slowly over 3 h. 2
Severe renal insufficiency (CrCl 20–30 mL/min): Limit total magnesium to 20 g per 48 h and obtain serum magnesium levels every 12–24 h.

Verify creatinine clearance ≥ 20 mL/min. 1, 2
Obtain baseline serum magnesium, potassium, calcium, and phosphate. (Circulation guideline) 4
Assess volume status and correct sodium/water deficits with IV isotonic saline before magnesium administration to avoid secondary hyperaldosteronism‑driven magnesium loss. 1, 2

Safety monitoring: Watch for hypotension, bradycardia, respiratory depression, and loss of deep tendon reflexes indicating magnesium toxicity. 2
Keep calcium chloride or calcium gluconate readily available to reverse toxicity if it occurs. 2
Cardiac monitoring: Continuous ECG monitoring is required when QTc is prolonged, arrhythmias are present, or QT‑prolonging drugs are co‑administered. (Circulation guideline) 4

Re‑measure serum magnesium 24–48 h after a cardiac emergency or severe deficiency correction. 2
For ongoing therapy, check magnesium 2–3 weeks after initiation, then every 3 months once stable. 2

Severe symptomatic hypomagnesemia (serum Mg < 0.50 mmol/L or < 1.2 mg/dL) with cardiac arrhythmias, seizures, or tetany. 2
Life‑threatening emergencies such as torsades de pointes, cardiac arrest, or ventricular arrhythmias—administer 1–2 g IV bolus over 5 min irrespective of measured level. 2, 3
QTc > 500 ms – aim to raise magnesium > 2 mg/dL as an anti‑torsadogenic measure. 2
Failure of oral therapy due to malabsorption (e.g., short bowel syndrome, high‑output stoma). 2
NPO status or severe gastrointestinal intolerance to oral magnesium. 2

Never give magnesium without confirming renal function; even modest impairment (CrCl 30–50 mL/min) can lead to accumulation with repeated dosing. 1
Correct magnesium before treating hypokalemia, because untreated hypomagnesemia impairs potassium re‑uptake and promotes renal potassium loss. 1, 2
Correct volume depletion and sodium deficits first; otherwise secondary hyperaldosteronism will cause ongoing renal magnesium wasting despite supplementation. 1, 2
Account for acute kidney injury superimposed on chronic kidney disease, as the combined reduction in excretory capacity markedly increases hypermagnesemia risk. 1